Heart failure (HF) is one of the most compelling and fastest-growing opportunities in the cardiovascular device market, with patient numbers climbing rapidly – more than six million live with HF in the US today and that number is expected to reach at least nine million by 2030 – and a large percentage of patients in the midstream of disease progression currently have few effective treatment options. By 2030, researchers estimate that the total annual economic cost of HF in the US will reach $97 billion, more than double what it was in 2010.
But the HF space also is an area ripe with innovation, and small, emerging companies are beginning to reap the...